thrombosis

Increased security with bivalirudin than with heparin alone in patients without ST segment.

Original title:&nbsp;Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.&nbsp;Reference:&nbsp;Bangalore S et al. CircCardiovascInterv. 2014;Epub ahead of print. Bivalirudin compared to unfractionated heparin as monotherapy is associated with a lower risk of<a href="https://solaci.org/en/2014/05/14/increased-security-with-bivalirudin-than-with-heparin-alone-in-patients-without-st-segment/" title="Read more" >...</a>

Angioplasty in sirolimus &#8211; eluting stent restenosis is safe and effective beyond the change of drug.

Original title:&nbsp;Sirolimius-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stents restenosis: Results from the ISAR-DESIRE 2 trial.&nbsp;Reference:&nbsp;Sebastian Kufner, et al. Cardiovascular Revascularization Medicine 2014, 15:69-75. &nbsp; DES restenosis has always generated a challenge and a puzzle when defining the strategy of revascularization by angioplasty: A quite used concept was to switch to<a href="https://solaci.org/en/2014/05/06/angioplasty-in-sirolimus-eluting-stent-restenosis-is-safe-and-effective-beyond-the-change-of-drug/" title="Read more" >...</a>

Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention show similar outcomes for ostial/midshaft lesion in Unprotected Left Main Coronary Artery

Original title:&nbsp;Long-Term Clinical Outcome Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesion in Unprotected Left main Coronary Artery From The DELTA Registry.&nbsp;Reference:&nbsp;Toru Nagamuna et al. JACC Cardiovascular Intervention. Article in Press Even though surgery remains the &ldquo;gold standard&rdquo; to treat UMCLA lesions, current guidelines have incorporated PCI as class IIa at ostium/midshaft level. The<a href="https://solaci.org/en/2014/04/04/coronary-artery-bypass-grafting-and-percutaneous-coronary-intervention-show-similar-outcomes-for-ostial-midshaft-lesion-in-unprotected-left-main-coronary-artery/" title="Read more" >...</a>

Deferred Stenting in Primary Angioplasty could reduce No Reflow Risk and Infarct Size.

Original:&nbsp;A Randomized Trial of Deferred Stenting versus Immediate Stenting to Prevent No-or Slow Reflow in Acute ST-Elevation Myocardial Infarction (DEFER-STEMI).&nbsp;Reference:&nbsp;David Carrick et al. J Am Coll Cardiol. 2014. Epub ahead of print. No Reflow physiopathology involves microvascular obstruction secondary to thrombus embolization, spasm or microvascular thrombosis, and happens in approximately 10% of PCI procedures. The<a href="https://solaci.org/en/2014/03/17/deferred-stenting-in-primary-angioplasty-could-reduce-no-reflow-risk-and-infarct-size/" title="Read more" >...</a>

Prophylactic vena cava filters in trauma patients effectively reduces pulmonary embolism

Original title:&nbsp;The effectiveness of prophylactic inferior vena cava filters in trauma patients: a systematic review and meta-analysis.&nbsp;Reference:&nbsp;Haut ER et al. JAMA Surg. 2014;149:194-202. Trauma is one of the strongest risk factors for pulmonary embolism (PE). Current guidelines recommend low molecular weight heparin therapy which have been proved effective; however, trauma patients often present high risk<a href="https://solaci.org/en/2014/03/12/prophylactic-vena-cava-filters-in-trauma-patients-effectively-reduces-pulmonary-embolism/" title="Read more" >...</a>

Best results of angioplasty with DES guided by IVUS versus angiography only

Original title:&nbsp;Intravascular Ultrasound-Guided Implantation of Drug-Eluting Stents to Improve Outcome. A Meta-Analysis.&nbsp;Reference:&nbsp;Jae-Sik Jang et al. J Am Coll Cardiol Intv 2014, epub ahead of print. Several previous studies and meta-analysis showed that implantation of conventional stents (BMS) intravascular ultrasound (IVUS) guided may decrease restenosis and clinical events. This information was not yet clear to drug-eluting<a href="https://solaci.org/en/2014/02/26/best-results-of-angioplasty-with-des-guided-by-ivus-versus-angiography-only/" title="Read more" >...</a>

At least one month of antiplatelet seems sufficient after a zotarolimus -eluting stent

Original title:&nbsp;Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following Resolute zotarolimus-eluting stent implantation.&nbsp;Reference:&nbsp;Silber S, Kirtane AJ, Belardi JA, et al. Eur Heart J. 2014; Epub ahead of print. Dual antiplatelet aggregation optimal time after implantation of a new generation drug-eluting stent (DES) is still discussed. This<a href="https://solaci.org/en/2014/02/25/at-least-one-month-of-antiplatelet-seems-sufficient-after-a-zotarolimus-eluting-stent/" title="Read more" >...</a>

The length of the stent is not an event predictor with the new generation of DES. It is the end of the Spot stenting?

Original title:&nbsp;Impact of the Stent Length on Long-Term Clinical Outcomes Following Newer-Generation Drug-Eluting Stent Implantation.&nbsp;Reference:&nbsp;Ik Jun Choi et al. Am J Cardiol 2014;113:457-464. Completely cover the lesion with a sufficiently long stent has been the preferred strategy that emerged from drug-eluting stents (DES). However, for the first-generation DES stent length has been a predictor of<a href="https://solaci.org/en/2014/02/20/the-length-of-the-stent-is-not-an-event-predictor-with-the-new-generation-of-des-it-is-the-end-of-the-spot-stenting/" title="Read more" >...</a>

3rd generation zotarolimus-eluting stent non- inferior to everolimus

Original title:&nbsp;Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomized, single-blind, multicentre, non-inferiority trial.&nbsp;Reference:&nbsp;Von Birgelen C et al. The Lancet. 2014; Epub ahead of print. In the 3rd generation zotarolimus-eluting stent, platform was modified to increase flexibility and make implant easier in complex lesions. This study was<a href="https://solaci.org/en/2014/02/13/3rd-generation-zotarolimus-eluting-stent-non-inferior-to-everolimus/" title="Read more" >...</a>

Almost 40 % of those who initially receive clopidogrel then switch to prasugrel or ticagrelor in clinical practice.

Original title:&nbsp;In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: Prevalence, predictors and short-term outcome.&nbsp;Reference:&nbsp;Dimitrios Alexopoulos et al. Am Heart J 2014;167:68-76.e2. Given the availability of 3 Oral P2Y12 receptor inhibitors (clopidogrel, prasugrel, and ticagrelor) with different safety and efficacy profiles, the change from one to another<a href="https://solaci.org/en/2014/02/07/almost-40-of-those-who-initially-receive-clopidogrel-then-switch-to-prasugrel-or-ticagrelor-in-clinical-practice/" title="Read more" >...</a>

Top